|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
She was being treated with gefitinib for lung adenocarcinoma positive for the epidermal growth factor receptor (EGFR) mutation L858R, and had multiple bone metastases.
|
26045851 |
2015 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Two of the 10 lung adenocarcinomas (20%) demonstrated epidermal growth factor receptor (EGFR) mutations, including 1 leucine-to-arginine substitution at codon 858 (L858R) in exon 21 and 1 codon 2235_2249 deletion (resulting in an in-frame deletion of 5 amino acids from position 746 to 750 [glutamic acid, leucine, arginine, glutamic acid, and alanine]; E746_A750del) in exon 19.
|
26682952 |
2016 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
IHC with the novel mutation-specific antibody could be used as a screening method to assess the EGFR L858R mutation status in primary lung adenocarcinoma.
|
25286755 |
2015 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ctDNA of EGFR-TKI sensitizing mutations (mEGFR), L858R substitution and Exon 19 deletion (E19d) mutation, was evaluated using droplet digital PCR (ddPCR) in 81 patients with lung adenocarcinoma which harbored mEGFR in the corresponding tumor tissues.
|
31647198 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All six L858R-mutant cavitary ADC patients had thick-wall cavity while thick-wall cavity was only identified in one thirds (3/9) of patients with 19DEL.
|
30352571 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR exon 20 insertion testing identifies a distinct subset of lung adenocarcinomas, accounting for at least 9% of all EGFR-mutated cases, representing the third most common type of EGFR mutation after exon 19 deletions and L858R.
|
23371856 |
2013 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The aim of this study was to compare the efficacy and toxicity of gefitinib as first-line therapy and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 (L858R) or exon 19 deletion of <i>EGFR</i> mutation.
|
28721096 |
2017 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Positive EGFR mutation status is a favorable prognostic factor in patients with surgically resected lung adenocarcinomas; however, EGFR mutation subtype (exon 21 L858R mutation or exon 19 deletion) exhibits no prognostic impact.
|
28826599 |
2017 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Seventy-seven patients of surgically resected lung adenocarcinoma were analysed for the EGFR exon 19 deletion and the L858R mutation, using mutant-enriched PCR, and for chromosomal imbalance alterations using comparative genomic hybridization.
|
20409020 |
2010 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Epidermal growth factor receptor mutation analysis revealed that the exon 21 L858R activating mutation was present in both the original lung adenocarcinoma and the metastatic SCLC.
|
20837450 |
2010 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the present study, we report cases of two synchronous lung adenocarcinomas composed of two distinct pathological subtypes with different EGFR gene mutations: a homozygous deletion in exon 19 of the papillary adenocarcinoma subtype and a point mutation of L858R in exon 21 of the tubular adenocarcinoma.
|
29090842 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Radical resection was performed and confirmed an EGFR exon 21 L858R lung adenocarcinoma.
|
29461911 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We report a case here that an advanced lung adenocarcinoma with L858R mutation responded well to pemetrexed rechallenge after acquired resistance of erlotinib.
|
24636847 |
2014 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Among the mutations of epidermal growth factor receptor (EGFR), deletions in exon 19 (DEL), and point mutations in exon 21 (L858R) predict the response to EGFR-tyrosine kinase inhibitors (TKIs) in primary lung adenocarcinoma.
|
21129809 |
2011 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We tested 2,142 lung adenocarcinoma specimens for the presence of EGFR exon 19 deletions and L858R.
|
21482987 |
2011 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Of 1127 patients with advanced lung adenocarcinoma harboring EGFR 19 del or L858R mutations, 532 received EGFR-TKI treatment and were included in this study.
|
27001083 |
2016 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Compare the complete (CR) and partial response (PR) rates, overall survival (OS), and progression-free survival (PFS) in Hispanic patients with lung adenocarcinoma treated with erlotinib with EGFR mutations (L858R or exon 19 deletion [Del19]) with and without concomitant EGFRamp.
|
30284706 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, the immunostaining with EGFR del E746-A750 and L858R mutation antibodies is a reliable screening method with high specificity and sensitivity for identifying the EGFR mutation in both resected and biopsied lung adenocarcinomas.
|
23465272 |
2013 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We have used unbiased phosphoproteomic approaches, based on quantitative mass spectrometry using stable isotope labeling with amino acids in cell culture (SILAC), to identify tyrosine phosphorylated proteins in isogenic human bronchial epithelial cells (HBECs) and human lung adenocarcinoma cell lines, expressing either of the two mutant alleles of EGFR (L858R and Del E746-A750), or a mutant KRAS allele, which are common in human lung adenocarcinomas.
|
18776048 |
2008 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
And then, 59 patients with advanced LAC harboring EGFR exon 19 deletions(del 19) or exon 21 point mutation(L858R) mutations received first-line treatment of gefitinib or erlotinib, the efficacy of treatment, and the progression-free survival (PFS) of these patients were recorded.
|
24297623 |
2014 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, MLH1 V384D polymorphism is associated with primary resistance to EGFR-TKIs in patients with EGFR L858R-positive lung adenocarcinoma and may potentially be a novel biomarker to guide treatment decisions.
|
25823662 |
2015 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thirty-three patients with recurrent postoperative EGFR-mutant lung adenocarcinoma (exon 19 deletion in 16, L858R in 15, G719C in 2 patients) treated with gefitinib were studied.
|
29767258 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Two hundred and six biopsies of primary lung ADC were subjected to EGFR mutation specific antibodies against del E746-A750 and L858R.
|
27241644 |
2016 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Driver mutations in the EGFR tyrosine kinase domain (mainly deletions in exon 19 and L858R mutation in exon 21) have been identified in lung adenocarcinomas, mostly in never smokers, at frequencies of 20-60%.
|
22594511 |
2012 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, retrospective analysis of 121 patients with lung adenocarcinoma to examine associations between serum SFTPD levels and clinical outcome indicated that in TKI-treated patients with lung cancer harboring EGFR mutations, including Ex19del or L858R, high serum SFTPD levels correlated with a lower number of distant metastases and prolonged overall survival and progression-free survival.
|
28745320 |
2017 |